Id |
Subject |
Object |
Predicate |
Lexical cue |
T58 |
0-49 |
Sentence |
denotes |
SARS-CoV-2/Finland/1/2020 whole-genome sequencing |
T59 |
50-304 |
Sentence |
denotes |
Nearly the complete coding region of SARS-CoV-2 (GenBank accession number: MT020781) was sequenced from the NPS collected on Day 4 (Table) and the complete coding region was sequenced from the virus isolate obtained after three passages in Vero E6 cells. |
T60 |
305-559 |
Sentence |
denotes |
The virus had 1 nt substitution C21707T compared with the reference strain Wuhan-Hu-1 collected in Wuhan China, December 2019 (NC_045512) [3] which had led to a histidine to tyrosine (H49Y) substitution in the N-terminal domain of the spike glycoprotein. |
T61 |
561-610 |
Sentence |
denotes |
Antibody response during the SARS-CoV-2 infection |
T62 |
611-728 |
Sentence |
denotes |
Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). |
T63 |
729-1014 |
Sentence |
denotes |
Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). |
T64 |
1015-1120 |
Sentence |
denotes |
Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. |
T65 |
1121-1231 |
Sentence |
denotes |
Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. |
T66 |
1232-1405 |
Sentence |
denotes |
While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). |
T67 |
1406-1555 |
Sentence |
denotes |
Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2). |
T68 |
1556-1660 |
Sentence |
denotes |
Figure 2 Immunofluorescence assay of serum samples, COVID-19 index case, Finland, January–February 2020 |
T69 |
1661-1696 |
Sentence |
denotes |
COVID-19: coronavirus disease 2019. |
T70 |
1697-1837 |
Sentence |
denotes |
Anti-SARS-CoV-2 IgM and IgG antibodies were detectable by immunofluorescence assay in samples from Days 9, 10 and 20 after onset of illness. |
T71 |
1838-1929 |
Sentence |
denotes |
Both IgM and IgG were found at a titre of 80 on Day 9, titres on Day 20 were 320 and 1,280. |
T72 |
1930-2052 |
Sentence |
denotes |
As an example, dilutions 1:20 and 1:160 from the Day 20 sample are shown for, respectively, IgM and IgG of the index case. |
T73 |
2053-2093 |
Sentence |
denotes |
Dilution 20 shown for the control serum. |
T74 |
2094-2287 |
Sentence |
denotes |
Mock- and SARS-CoV2-infected Vero E6 cells collected on Day 6 post infection were lysed in Laemmli sample buffer, and Western blotting (WB) of lysates was performed as described previously [4]. |
T75 |
2288-2397 |
Sentence |
denotes |
At 1:200 dilution, the convalescent serum on Day 20 identified SARS-CoV2 N, S and E protein bands (Figure 3). |
T76 |
2398-2486 |
Sentence |
denotes |
At higher exposure, all bands were detectable even at 1:1,600 serum dilution (Figure 3). |
T77 |
2487-2650 |
Sentence |
denotes |
Figure 3 Western blot of mock- and SARS-CoV-2 infected Vero E6 cells using patient serum collected 20 days after onset of symptoms, Finland, January–February 2020 |
T78 |
2651-2748 |
Sentence |
denotes |
Top left panel: total protein staining (Ponceau S) of the nitrocellulose membrane before probing. |
T79 |
2749-2842 |
Sentence |
denotes |
Top right panel: strips probed with different dilutions of the patient serum at low exposure. |
T80 |
2843-2926 |
Sentence |
denotes |
Bottom panel: the same membranes individually contrasted for higher band intensity. |
T81 |
2927-3096 |
Sentence |
denotes |
The arrows indicate SARS-CoV-2 proteins, the labelling assumes that the migration of SARS-CoV-2 proteins was similar to that of Vero E6-expressed SARS-CoV proteins [23]. |
T82 |
3097-3181 |
Sentence |
denotes |
The bands migrating at ca 110 and 90 kDa probably represent S1 and S2, respectively. |
T83 |
3182-3239 |
Sentence |
denotes |
Marker M: Precision Plus Dual Colour Standards (Bio-Rad). |
T84 |
3240-3369 |
Sentence |
denotes |
The detection was done using Odyssey Infrared Imaging System (LI-COR) using goat anti-human IR800 conjugate at 1:10,000 dilution. |
T85 |
3370-3485 |
Sentence |
denotes |
SARS-CoV-2-specific neutralising antibody levels were measured in duplicate with the MN test in a BSL-3 laboratory. |
T86 |
3486-3661 |
Sentence |
denotes |
The serum samples were heat-inactivated at 56 °C for 30 min and 2-fold serially diluted starting from 1:4 in EMEM supplemented with 2% of heat-inactivated FBS and antibiotics. |
T87 |
3662-3800 |
Sentence |
denotes |
Fifty plaque‐forming units (PFU) of the SARS-CoV-2/Finland/1/2020 strain were added to the serum dilutions and incubated for 1 h at 37 °C. |
T88 |
3801-3945 |
Sentence |
denotes |
Vero E6 cells (5 × 104/well) were added to the virus–serum mix, and the mixture was incubated in 96-well plates for 4 days at 37 °C with 5% CO2. |
T89 |
3946-3981 |
Sentence |
denotes |
Neutralisation was assessed by CPE. |
T90 |
3982-4134 |
Sentence |
denotes |
The neutralisation endpoint was determined as the 50% endpoint of the serum that inhibited the SARS-CoV-2 infection observed by CPE of inoculated cells. |
T91 |
4135-4252 |
Sentence |
denotes |
Diagnostic serum samples from the index case and her three asymptomatic close contacts were studied with the MN test. |
T92 |
4253-4331 |
Sentence |
denotes |
During the acute phase of infection, no neutralising antibodies were detected. |
T93 |
4332-4458 |
Sentence |
denotes |
The patient seroconverted for neutralising antibodies between Day 4 and 9, with the titre increasing to 160 on Day 20 (Table). |
T94 |
4459-4544 |
Sentence |
denotes |
The serum specimens were confirmed not to be toxic or infective to the cells as such. |
T95 |
4545-4622 |
Sentence |
denotes |
Serum samples taken from the three close contacts tested negative in MN test. |
T96 |
4623-4738 |
Sentence |
denotes |
We also tested serum samples collected in 2019 from 83 Finnish subjects aged 4 to 89 years and all tested negative. |
T97 |
4739-4913 |
Sentence |
denotes |
Sera known to be positive for IgG against human coronavirus OC43 and 229E [5] and rabbit or guinea pig antibody against SARS-CoV N protein [6] could not neutralise the virus. |
T98 |
4915-4932 |
Sentence |
denotes |
Ethical statement |
T99 |
4933-5243 |
Sentence |
denotes |
The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the Finnish Personal Data Act (Finlex 523/1999) The Finnish Communicable Diseases Act (Finlex 1227/2016) allows sampling for diagnostic and surveillance purposes. |
T100 |
5244-5437 |
Sentence |
denotes |
The convalescent serum sample was obtained on 14 February through informed consent of the patient and research permits (TYH2018322, TYH2019263) from the Helsinki University Hospital Laboratory. |
T101 |
5438-5498 |
Sentence |
denotes |
Finnish population serum samples were collected during 2019. |
T102 |
5499-5644 |
Sentence |
denotes |
The study protocol was approved by the Ethics Committee of the Department of Medicine, Helsinki University Hospital (Permission 433/13/03/00/15). |
T103 |
5645-5732 |
Sentence |
denotes |
Serum samples of University of Helsinki staff members were used under informed consent. |